Efficacy and safety of antidepressant's use in the treatment of depressive episodes in bipolar disorder - Review of research;Skutecznos̈ć i bezpieczeństwo stosowania leków przeciwdepresyjnych w terapii epizodu depresyjnego w przebiegu choroby afektywnej dwubiegunowej - Przegląd wyników badań

Psychiatria Polska

Volumn 49, Issue 6, 2015, Pages 1223-1239

  Antosik Wójcińska, Anna ^a   Stefanowski, Bogdan ^a   ͆więcicki, Łukasz ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Antidepressant drugs; Bipolar depression; Bipolar disorder

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADVERSE OUTCOME; BIPOLAR DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MANIA; MEDLINE; MONOTHERAPY; MOOD DISORDER; REMISSION; REVIEW; TREATMENT DURATION; BIPOLAR DISORDER; COMPLICATION; CONTRAINDICATIONS; DEPRESSION; FEMALE; MALE; SEVERITY OF ILLNESS INDEX;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; DEPRESSION; FEMALE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 84950991086     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: 10.12740/PP/37914     Document Type: Review

References (58)

1. Thase ME. Bipolar depression: diagnostics and treatment considerations. Dev. Psychopathol. 2006; 18: 1213-1230.
2. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD. i wsp. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 2003; 60: 261-269.
3. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA. i wsp. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 2002; 59: 530-537.
4. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS. i wsp. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007; 9: 531-535.
5. López P, Mosquera F, de León J, Gutiérrez M, Ezcurra J, Ramírez F. i wsp. Suicide attempts in bipolar patients. J. Clin. Psychiatry 2001; 62: 963-966.
6. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA. i wsp. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry 2005; 62: 1322-1330.
7. Maj M, Pirozzi R, Magliano L, Bartoli ML. The prognostic significance of switching in patients with bipolar disorder: a 10-year prospective follow-up study. Am. J. Psychiatry 2002; 159: 1711-1717.
8. Ghaemi SN, Rosenquist KJ, Ko JY, Baldassano CF, Kontos NJ, Baldessarini RJ. Antidepressant treatment in bipolar versus unipolar depression. Am. J. Psychiatry 2004; 161: 163-165.
9. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 2004; 161: 1537-1547.
10. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am. J. Psychiatry 1987; 144: 1403-1411.
11. Altshuler L, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M. i wsp. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J. Clin. Psychiatry 2001; 62: 612-616.
12. Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA. i wsp. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry 2003; 160: 1252-1262.
13. Compton MT, Nemeroff CB. The treatment of bipolar depression. J. Clin. Psychiatry 2000; 61(supl. 9): 57-67.
14. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry 2000; 157: 124-126.
15. Calabrese JR, Rapport DJ, Kimmel SE, Shelton MD. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur. Neuropsychopharmacol. 1999; 9(supl. 4): S109-S112
16. Tondo L, Baldessarini RJ, G. Vazquez, Lepri B, Visioli C. Clinical responses to antidepressants among 1036 acute depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr. Scand. 2013; 127(5): 355-364.
17. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. J. Affect. Disord. 2005; 87(1): 121-130.
18. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of Bipolar II Disorder: a randomized, double-blind, placebo-substitution study. Am. J. Psychiatry 2010; 167(7): 792-800.
19. Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr. Scand. 2010; 121: 201-208.
20. Vieta E, Martinez-Arán A, Goikolea JM, Torrent C, Colom F, Benabarre A. i wsp. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry 2002; 63(6): 508-512.
21. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L. i wsp. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N. Eng. J. ed.. 2007; 356(4): 1711-1722.
22. Parker G ,Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J. Affect. Disord. 2006; 92(2-3): 205-214.
23. Agosti V, Stewart JW. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int. Clin. Psychopharmacol. 2007; 22(5): 309-311.
24. Pihatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J. Affect. Disord. 2010; 126(3): 453-457.
25. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M. i wsp. A double-blind placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression EMBOLDEN II). J. Clin. Psychiatry 2010; 71(2): 163-174.
26. Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J. Clin. Psychiatry 2011; 72(2): 156-167.
27. Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME. i wsp. Antidepressant discontinuation in bipolar depression: a systematic treatment enhancement program for bipolar disorder(STEP-BD) randomized clinical trial of long-term effectiveness and safety. J. Clin. Psychiatry 2010; 71(4): 372-380.
28. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am. J. Psychiatry 1987; 144: 1403-1411.
29. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manicdepressive cycle and changes caused by treatment. Pharmakopsychiatr. Neuropsychopharmakol. 1980; 13: 156-167.
30. Goodwin FK, Jamison KR. Manic-depressive illness. Second edition. New York: Oxford University Press; 2007.
31. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch. Pediatr. Adolesc. Med. 2004; 158: 773-780.
32. Baldessarini RJ, Faedda GL, Hennen J. Risk of mania with serotonin reuptake inhibitors vs. tricyclic antidepressants in children, adolescents and young adults. Arch. Pediatr. Adolesc. Med. 2005; 159: 298-299.
33. Koukopoulos A, Koukopoulos AE. Agitated depression as a mixed state and the problem of melancholia. Psychiatr. Clin. North Am. 1999; 22: 547-564.
34. Bottlender R, Sato T, Kleindienst N, Strauss A, Möller HJ. Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. J. Affect. Disord. 2004; 78: 149-155.
35. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch. Pediatr. Adolesc. Med. 2004; 158: 773-780.
36. Lewis DA, Nasrallah HA. Mania associated with electroconvulsive therapy. J. Clin. Psychiatry 1986; 47: 366-367.
37. Akiskal HS, Djenderedjian AM, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am. J. Psychiatry 1977; 134: 1227-1233.
38. Kukopulos A, Reginaldi D, Laddomada P, Minnai G, Floris G, Reginaldi D. i wsp. Rapid cyclers, temperament, and antidepressants. Compr. Psychiatry 1983; 24: 249-258.
39. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE Jr. i wsp. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry 2006; 163(2): 232-239.
40. Bottlender R, Rudolf D, Jäger M, Strauss A, Möller HJ. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur. Psychiatry 2002; 12: 200-205.
41. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 2004; 9(161): 1537-1547.
42. Viktorin A, Lichtenstein P, Thase ME, Larsson H, Lundholm C, Magnusson PK. i wsp. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am. J. Psychiatry 2014; 171(10): 1067-1073.
43. Tondo L, Vazquez G, Baldessarin RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic revive. Acta Psychiatr. Scand. 2010: 121: 404-414.
44. Truman CJ, Goldeberg JF, Ghaemi SN, Ghaemi SN, Baldassano CF, Wisniewski SR, Dennehy EB. i wsp. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the systematic treatment enhancement program for bipolar disorder (STEP-BD). J. Clin. Psychiatry 2007; 68(10): 1472-1479.
45. Leon AC, Fiedorowicz JG, Solomon DA, Li C, Coryell WH, Endicott J. i wsp. Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders. J. Clin. Psychiatry 2014; 7(75): 720-726.
46. Bond DJ, Noronha MM, Kaucer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in Bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J. Clin. Psychiatry 2008; 69(10): 1589-1601.
47. Valentí M, Pacchiarotti I, Rosa AR. Bonnín CM, Popovic D, Nivoli AM. i wsp. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord. 2011; 13(2): 145-154.
48. Pacchiarotti I, Mazzarini L, Kotzalidis GD, Valentí M, Nivoli AM, Sani G. i wsp. Mania and depression: mixed, not stirred. J. Affect. Disord. 2011; 133: 105-113.
49. Sussman M, Friedman M, Korn JR, Hassan M, Kim J, Menzin J. The relationship between use of antidepressants and resource utilization among patients with manic or mixed bipolar disorder episodes: findings from a managed care setting. J. Affect. Disord. 2012; 138: 425-432.
50. Dudek D, Siwek M. Depresja w chorobie afektywnej dwubiegunowej. Choroba afektywna dwubiegunowa - wyzwania diagnostyczne. Poznań: Termedia; 2012.
51. Dudek D. Leczenie depresji w przebiegu choroby afektywnej dwubiegunowej. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Gdańsk: Via Medica; 2011.
52. Post RM, Altshuler LL, Leverich GS. Frye MA, Nolen WA, Kupka RW. i wsp. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br. J. Psychiatry 2006; 189: 124-131.
53. Mahli GS, Adams D, Lampe L, Paton M, O'Connor N, Newton LA. i wsp. Clinical recommendations for bipolar disorder. Acta Psychiatr. Scand. Suppl. 2009; 439: 27-46.
54. Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA. i wsp. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am. J. Psychiatry 2003; 160: 1252-1262.
55. Altshuler LL, Post RM, Hellemann G, Leverich GS, Nolen WA, Frye MA. i wsp. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded ,randomized study. J. Clin. Psychiatry 2009; 70: 450-457.
56. Dudek D. Leczenie depresji w przebiegu choroby afektywnej dwubiegunowej. W: Jarema M. red. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Gdańsk: Via Medica; 2011.
57. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C. i wsp. Canadian Network for Mood and Anxiety Treatments(CANMAT) and International Society for Bipolar Disorders(IBSD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013; 15: 1-44.
58. Pacchiarotti I, Bond D, Baldessarini R. Nolen WA, Grunze H, Licht RW. I wsp. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 2013; 170(11): 1249-1262.